The yin and yang of viruses and interferons

Trends in Immunology

Volumn 33, Issue 4, 2012, Pages 190-197

  Wang, Ben X ^a,b   Fish, Eleanor N ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; BETA INTERFERON;

HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; INFLUENZA A; INNATE IMMUNITY; NONHUMAN; REVIEW; VIRAL CLEARANCE; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84862794613     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.01.004     Document Type: Review

References (87)

1. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
2. Kumar H., et al. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30:16-34.
3. Platanias L. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat. Rev. Immunol. 2005, 5:375-386.
4. Brass A.L. IFITM proteins mediate the innate immune response to influenza A H1N1 virus, West Nile virus and dengue virus. Cell 2009, 139:1243-1254.
5. Sakamoto E., et al. Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2. J. Leukoc. Biol. 2005, 78:301-309.
6. Kropp K.A., et al. Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state. J. Virol. 2011, 85:10286-10299.
7. Martinez J., et al. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J. Immunol. 2008, 180:1592-1597.
8. + Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206:1589-1602.
9. Swanson C.L., et al. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J. Exp. Med. 2010, 207:1485-1500.
10. Matsuyama N., et al. The dinucleotide microsatellite polymorphism of IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol. Res. 2003, 25:221-225.
11. Hijikata M., et al. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000, 43:124-127.
12. Ren S., et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection. Antiviral Res. 2011, 89:232-237.
13. Persico M., et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 2008, 57:507-515.
14. Narayanan K., et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 2008, 82:4471-4479.
15. Hale B.G., et al. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008, 89:2359-2376.
16. Baril M., et al. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J. Virol. 2009, 83:1299-1311.
17. Wang H., Ryu W.S. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog. 2010, 6:e1000986.
18. Paladino P., et al. Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS ONE 2010, 5:e10428.
19. Frieman M., et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 2007, 81:9812-9824.
20. Jia D., et al. Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS ONE 2010, 5:e13927.
21. Johnson K.E., et al. Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology 2008, 374:487-494.
22. Kamitani W., et al. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat. Struct. Mol. Biol. 2009, 16:1134-1140.
23. Wathelet M.G., et al. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J. Virol. 2007, 81:11620-11633.
24. Devaraj S.G., et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 2007, 282:32208-32221.
25. Siu K.L., et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. 2009, 284:16202-16209.
26. Wang B.X., et al. Clinical application of interferons. Viruses and Interferon: Current Research 2011, 235-262. Horizon Press. K.L. Mossman (Ed.).
27. Wang B.X., et al. Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 2011, 31:545-552.
28. Fish E.N. Definition of receptor binding domains in interferon-alpha. J. Interferon Res. 1992, 12:257-266.
29. Korn A., et al. A three-dimensional model of consensus sequence interferon-alpha. J. Interferon Res. 1994, 14:1.
30. Uze G., et al. Domains of interaction between alpha interferon and its receptor components. J. Mol. Biol. 1994, 243:245-257.
31. Piehler J., Schreiber G. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. J. Mol. Biol. 1999, 19:223-237.
32. Runkel L., et al. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J. Interferon Cytokine Res. 2001, 21:931-941.
33. Deonarain R., et al. Interferon-α/β-receptor interactions: a complex story unfolding. Curr. Pharm. Des. 2002, 8:2131-2137.
34. Roisman L.C., et al. Mutational analysis of the IFNAR1 binding site on IFNα2 reveals the architecture of a weak ligand-receptor binding site. J. Mol. Biol. 2005, 353:271-281.
35. Chill J.H., et al. The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure 2003, 11:791-802.
36. Pan M., et al. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists. Biochemistry 2008, 47:12018-12027.
37. Fish E.N., et al. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem. Biophys. Res. Commun. 1983, 112:537-546.
38. Fish E.N., et al. The role of three domains in the biologically active configuration of human interferon alpha. J. Interferon Res. 1989, 9:97-114.
39. Thomas C., et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011, 146:621-632.
40. Kumaki Y., et al. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem. Biophys. Res. Commun. 2008, 371:110-113.
41. Sjogren M.H., et al. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig. Dis. Sci. 2005, 50:727-732.
42. Melian E.B., et al. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001, 61:1661-1691.
43. Blatt L.M., et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J. Interferon Cytokine Res. 1996, 16:489-499.
44. Stockman L.J., et al. SARS: systemic review of treatment effects. PLoS Med. 2006, 3:e343.
45. Poutanen S.M., et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 2003, 348:1995-2005.
46. Loufty M.R., et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome. JAMA 2003, 290:3222-3228.
47. Zorzitto J., et al. Characterization of the antiviral effects of interferon-alpha against a SARS-like Coronavirus infection in vitro. Cell Res. 2006, 16:220-229.
48. van der Vries E., et al. The potential for multidrug-resistant influenza. Curr. Opin. Infect. Dis. 2011, 24:599-604.
49. Calatayud L., et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg. Infect. Dis. 2011, 17:1807-1815.
50. Fiebig L., et al. Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010. Euro. Surveill. 2011, 16:pii:19941.
51. de Jong M.D., et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353:2667-2672.
52. Gao L., et al. A randomized controlled trial of low-dose recombinant human interferon alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine 2010, 28:4445-4451.
53. Tsubota A., et al. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J. Gastroenterol. 2011, 17:419-432.
54. Sanjo M., et al. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. J. Med. Virol. 2010, 82:1364-1370.
55. Kitamura S., et al. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir. Ther. 2010, 15:1087-1097.
56. Kim M.J., Yoo J.Y. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J. Immunol. 2010, 185:4311-4318.
57. Vyas J., et al. Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA. RNA 2003, 9:858-870.
58. Wong V.W., et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:1945-1953.
59. Lau G.K.K., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005, 352:2682-2695.
60. Rijckborst V., et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am. J. Gastroenterol. 2010, 105:1762-1769. PARC Study Group.
61. Roberts C.M. Increasing proportion of herpes simplex virus type I as a cause of genital herpes infection in college students. Sex. Transm. Dis. 2003, 30:797-800.
62. Steiner I. Herpes simplex virus encephalitis: new infection or reactivation?. Curr. Opin. Neurol. 2011, 24:268-274.
63. 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection. J. Virol. 2004, 78:7653-7666.
64. Sànchez R., Mohr I. Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. J. Virol. 2007, 81:3455-3464.
65. Huang W.Y., et al. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T cell-independent manner. J. Gen. Virol. 2010, 91:591-598.
66. Langston A.A., et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 2002, 99:1085-1088.
67. Bacon T.H., et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 2003, 16:114-128.
68. Kalil A.C., et al. Use of interferon-α in patients with West Nile encephalitis: report of 2 cases. Clin. Infect. Dis. 2005, 40:764-766.
69. Julander J.G., et al. Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob. Agents Chemother. 2011, 55:2067-2073.
70. Jahrling P.B., et al. Evaulation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 1999, 179(Suppl. 1):S224-S234.
71. Ghislain J., et al. Evidence for glycosphingolipid modification of the type 1 IFN receptor. J. Immunol. 1994, 153. 3655-3563.
72. Kumaran J., et al. A structural basis for interferon-α-receptor interactions. FASEB J. 2007, 21:3288-3296.
73. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
74. Xu D., et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009, 30:802-816.
75. Fensterl V., et al. The ISG56/IFIT1 gene family. J. Interferon Cytokine Res. 2011, 31:71-78.
76. Huang I.C., et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011, 7:e1001258.
77. Singh R., et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J. Virol. 2011, 85:208-216.
78. Jia D., et al. Interferon-inducible Stat2 activation of JUND and CLDN4: mediators of IFN responses. J. Interferon Cytokine Res. 2007, 27:559-565.
79. Hervas-Stubbs S., et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 2011, 17:2619-2627.
80. Shin E.C., et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J. Clin. Invest. 2006, 116:3006-3014.
81. Keir M.E., et al. IFN-α secretion by type 2 predendritic cells up-regulates MHC Class I in the HIV-1-infected thymus. J. Immunol. 2002, 168:325-331.
82. Selleri C., et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997, 89:957-964.
83. Gao Y., et al. Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-β. Blood 2009, 114:2623-2631.
84. Karti S.S., et al. Effect of interferon-alpha(2a) on neutrophil adhesion and phagocytosis in chronic myeloid leukemia and Behçet's disease. Clin. Rheumatol. 2002, 21:211-214.
85. Liang S., et al. IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 2003, 23:190-199.
86. Marshall J.D., et al. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology 2006, 117:38-46.
87. Taylor D.R., et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.